The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 352:2756-2757 June 30, 2005 Number 26
NextNext

Polycystic Ovary Syndrome

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Ehrmann, D. A.
-PubMed Citation
To the Editor: Ehrmann's review article on the polycystic ovary syndrome (March 24 issue)1 misses the liver issue. Alanine aminotransferase activity is abnormal in 30 percent of patients with the polycystic ovary syndrome in whom causes other than nonalcoholic fatty liver disease were excluded.2 The high rates of prevalence of impaired glucose tolerance and type 2 diabetes mellitus among patients with the polycystic ovary syndrome confirm that chronic nonalcoholic liver disease and its consequences are an important issue in these patients.3 Accordingly, the use of thiazolidinediones to treat patients with the polycystic ovary syndrome requires serious caution. The Food and . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.